Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy X4 Pharmaceuticals (XFOR) stocks

Learn how to easily invest in X4 Pharmaceuticals stocks.

X4 Pharmaceuticals is a biotechnology business based in the US. X4 Pharmaceuticals stocks (XFOR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.24 – a decrease of 2.03% over the previous week. X4 Pharmaceuticals employs 40 staff and has a market cap (total outstanding stock value) of $245.6 million.

How to buy X4 Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – XFOR. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners


National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

X4 Pharmaceuticals stock price (NASDAQ:XFOR)

Use our graph to track the performance of XFOR stocks over time.

X4 Pharmaceuticals shares at a glance

Information last updated 2023-05-28.
Latest market close$1.93
52-week range$0.65 - $2.41
50-day moving average $1.35
200-day moving average $1.30
Wall St. target price$3.66
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.94

Buy X4 Pharmaceuticals stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
National Bank Direct Brokerage
Finder Rating:
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Is it a good time to buy X4 Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

X4 Pharmaceuticals price performance over time

Historical closes compared with the close of $1.93 from 2023-05-30

1 week (2023-05-25) -3.98%
1 month (2023-05-01) 22.93%
3 months (2023-03-01) 103.16%
6 months (2022-12-01) 34.03%
1 year (2022-06-01) 55.65%
2 years (2021-06-01) -79.68%
3 years (2020-06-01) 8.62
5 years (2018-06-01) 17.51
[/expander_content] [/expander]

X4 Pharmaceuticals financials

Gross profit TTM $3 million
Return on assets TTM -53.34%
Return on equity TTM -189.21%
Profit margin 0%
Book value $0.42
Market capitalisation $245.6 million

TTM: trailing 12 months

X4 Pharmaceuticals share dividends

We're not expecting X4 Pharmaceuticals to pay a dividend over the next 12 months.

Have X4 Pharmaceuticals's shares ever split?

X4 Pharmaceuticals's shares were split on a 1:6 basis on 14 March 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your X4 Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for X4 Pharmaceuticals shares which in turn could have impacted X4 Pharmaceuticals's share price.

X4 Pharmaceuticals share price volatility

Over the last 12 months, X4 Pharmaceuticals's shares have ranged in value from as little as $0.65 up to $2.413. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while X4 Pharmaceuticals's is 0.2783. This would suggest that X4 Pharmaceuticals's shares are less volatile than average (for this exchange).

X4 Pharmaceuticals overview

X4 Pharmaceuticals, Inc. , a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co. , Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site